You must log in or register to comment.
could be manufactured for 89 cents to $4.73 for a month’s supply
That compares to the monthly US list price of $968.52 for Ozempic, a weekly injection.
I got semaglutide (Rybelsus, the pill form) prescribed for type 2 diabetes. The list price in Spain for a 30 pill format (a month’s worth) is around 130€ ($140) without discounts. Thanks to the prescription, I get it for free ($0.00)… which turns out to be closer to its actual value. Interesting 🤔
deleted by creator
Wonder how much public funding was used toward the research.
nothing on this page mentions anything about Ozempic, semaglutide, or the amounts of funding received. the closest thing is a list of current diabetes research projects with, again, no amounts listed and no clear relation to ozempic.
deleted by creator
deleted by creator
They get you coming and going. Plaster the media with ads for junk food, then really grind you down when you are sick and unhealthy
You believe the fast food companies work in cahoots with the obesity pharma companies?
Sounds like a match made in hell
Before being an appetite suppressant, it is a medication for diabetes.
The problem is not the margin Novo Nordisk makes on an appetite suppressant, contrary to what the headline says.
The twofold problem is the margin on a diabetes drug, which weighs heavily on patients and health insurers around the world. And the potential supply problems for diabetics, when a vital drug is sold as a miracle weight-loss remedy.
it’s a polypeptide with two unnatural aminoacids, this aint rocket surgery. doses are in low miligram range, so still rather on the pricey side
The Egg of Columbus does spring to mind, reading your comment.
one of these aminoacids has a rather fancy linker attached to another two aminoacids, getting this to work was probably the hardest part of development of this compound. once you have structure it’s a solved problem, esp with peptide coupling chemistry, it can be literally printed on solid substrate residue by residue (humans make it cheaper, greener and on larger scale tho)
This is of course their MO. They were making Insulin for pennies per vial for years and selling it for hundreds of dollars per. It’s funny how they’re allowed to keep doing this to us and they probably always will because the US right thinks the immoral thing is not letting vampires have a suck whenever they want it. Obesity and Diabetes are a couple of the largest killers around, to say nothing of the losses in Quality of Life they cause. It’s just insane that we refuse to regulate prices for drugs that would relieve immeasurable suffering and death because CEOs gotta have a nicer Yacht or how is life any fair?
deleted by creator
The left is definitely more open to considering regulation. It’s not even close. The right thinks that regulation is a four letter word and they’re generally not a fan of those either. It’s disingenuous to both sides everything. Much of the time where the left allows a carveout for vampirism, it’s because it’s the best compromise they can mange to a given end given that the right is out there swabbing their throats and getting all hot and bothered waiting for daddy Drac to come and give it to them, not because it’s their preference that we allow unfettered late-stage capitalism to destroy lives. Again, it’s disingenuous to claim that their pragmatism in the face of unreasonable actors is the same as being the unreasonable actors (and I am well aware that there are exceptions that prove the rule on both sides of the isle, so 🤷♂️)
…and lest anyone think that this problem isn’t solved with government regulation, I invite you to look at the medication situation in nearly any other country in the world where by and large they are not afraid of regulation for the same drug companies that are fucking us sideways in the US and see how much cheaper and better their access to medications is solely because they’re willing to support that maybe there is a greater public good than shareholder profits.
deleted by creator
At this point they’re only wagging their fingers to make it appear as though they’re considering regulation.
Again, it’s disingenuous to claim that their pragmatism in the face of unreasonable actors is the same as being the unreasonable actors. What are the left supposed to do? Pull a Trump and pretend that the laws and systems that make our country don’t exist and just say that what they want is law and ignore that half the country is electing morons who will fight them at every turn? That’s not how it works and frankly I wouldn’t want it to work that way because it’s just incredibly dangerous. They’re trying to work within a system where the right has learned they can con half the country into believing they’re doing their job while they sit back and do their damnedest to ensure that the government doesn’t function at all because that’s the only way that conservatives can stop progress at this point with their platforms being as unpopular as they are.
deleted by creator
A lot of stuff can be made a lot cheaper than it’s sold.
alt link?
deleted by creator
🤖 I’m a bot that provides automatic summaries for articles:
Click here to see the summary
Ozempic could be profitably produced for less than $5 a month even as maker Novo Nordisk A/S charges almost $1,000 in the US, according to a study that revives questions about prices for top-selling treatments for diabetes and obesity.
The blockbuster drug could be manufactured for 89 cents to $4.73 for a month’s supply, figures that include a profit margin, researchers at Yale University, King’s College Hospital in London and the nonprofit Doctors Without Borders reported in the journal JAMA Network Open.
The study extends research showing how steep US markups are for GLP-1 drugs like Ozempic and Wegovy and underlines longstanding criticism of prices for diabetes therapies, especially insulin.
By some estimates, however, the reductions made those products more profitable because they eliminated rebates paid to pharmacy benefit managers, the middlemen who negotiate prices for payers and employers.
State health plans and Medicaid offices are seeing growing bills for Ozempic and its sister drug Wegovy, raising questions about whether the increases in cost are sustainable.
In January, North Carolina cut off coverage of anti-obesity medicines for state employees, citing soaring costs and lack of agreement on pricing from drugmakers.
Saved 76% of original text.
deleted by creator
